Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies

Author (year) Region Type Actinomycin D-based regimen Methotrexate-based regimen
Treatment No. CR Treatment No. CR
Kang (2019) China RCT Act-D, IV, 10 μg/kg daily for 5 days 49 43 MTX, IM, 0.4 mg/kg daily for 5 days 49 41
Yarandi (2016) Iran RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 30 24 MTX, IV, 0.4 mg/kg daily for 5 days 32 25
Shahbazian (2014) Iran RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 15 13 MTX, IM, 40 mg/m2 weeklyMTX, IM, 40 mg/m2 weekly 15 8
Mousavi (2012) Iran RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 50 45 MTX, IM, 0.4 mg/kg daily for 5 days 25 17
Lertkhachonsuk (2009) Thailand RCT Act-D, IV, 10 μg/kg daily for 5 days 20 20 MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 0.1 mg/kg on days 2, 4, 6 and 8 19 14
Osborne (2011) Multi-nation RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 109 76 MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly 107 57
Gilani (2005) Iran RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 18 16 MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly 28 14
Schink (2020) U.S. RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 28 22 MTX, IV, 0.4 mg/kg daily for 5 days 26 23
Verhoef (2017) Netherlands Non-RCT Act-D, IV, 1.25–2 mg/m2 biweeklyAct-D, IV, 1.25–2 mg/m2 biweekly 34 29 MTX, IM, 50 mg biweekly 4 1
Al-Husaini (2014) Arabia Non-RCT Act-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 0.5 mg daily for 5 daysAct-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 0.5 mg daily for 5 days 23 20 MTX, IM, 1 mg/kg weekly or MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 73 39
Uberti (2015) Brazil Non-RCT Act-D, IV, 1.25–2 mg/m2 biweekly 79 53 MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, Oral, 15 mg on days 2, 4, 6 and 8 115 87
Abrao (2008) Brazil Non-RCT Act-D, IV, 12 μg/kg daily for 5 days 42 30 MTX, IM, 20 mg/m2 daily for 5 daysMTX, IM, 20 mg/m2 daily for 5 days 42 29
Yarandi (2008) Iran Non-RCT Act-D, IV, 1.25 mg/m2 biweeklyAct-D, IV, 1.25 mg/m2 biweekly 50 45 MTX, IM, 30 mg/m2 weeklyMTX, IM, 30 mg/m2 weekly 81 39
Baptista (2012) Brazil Non-RCT Act-D, IV, 12 μg/kg daily for 5 days 20 18 MTX, IM, 50 mg + FA, oral, 15 mg, for 8 days 20 10
Lee (2017) South Korea Non-RCT Act-D, IV, 1.25 mg/m2 biweekly or Act-D, IV, 12 μg/kg daily for 5 days 18 15 MTX, IM, 1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 0.1 mg/kg on days 2, 4, 6 and 8 or MTX, IM, 50 mg/m2 weekly 53 33
Matsui (2005) Japan Non-RCT Act-D, IV, 8.5-10μg/kg daily for 5 days 26 20 MTX, IM, 0.35–0.4 mg/kg daily for 5 days 133 91
Matsui (2005) Japan Non-RCT Act-D, IV, 8.5-10μg/kg daily for 5 days 26 20 MTX, IM, 0.85-1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 85-100μg/kg on days 2, 4, 6 and 8 24 14
Matsui (1998) Japan Non-RCT Act-D, IV, 8.5-10μg/kg daily for 5 days 25 21 MTX, IM, 0.35–0.4 mg/kg daily for 5 days 121 89
Matsui (1998) Japan Non-RCT Act-D, IV, 8.5-10μg/kg daily for 5 days 25 21 MTX, IM, 0.85-1 mg/kg on days 1, 3, 5 and 7 + FA, IM, 85-100μg/kg on days 2, 4, 6 and 8 20 12
  1. CR Complete remission, RCT Randomized controlled trials, non-RCT non-randomized studies, Act-D Actinomycin-d, MTX Methotrexate, IM Intramuscular, IV Intravenous